Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | November 05, 2024 | November 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date November 05, 2024 · Filed November 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 559 |
Reported balance
After 2024-11-05 transaction · row 1
1 source rowRow 1 · 2024-11-05 · Sale · Disposed 61 · Balance 559 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2024 Filed Nov 7, 2024 19:12 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | SaleCOMMON STOCK, PAR VALUE $0.0001 | 61 | $2.24 | $136.64 |
DisclosureSEC source: 0001104659-24-115424 · tm2427866-1_4seq1.xml · nonDerivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559 Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 16:15 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 497 | $2.50 | $1,242.50 |
DisclosureSEC source: 0001104659-24-104931 · tm2425333-1_4seq1.xml · nonDerivative · entry 2 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620 F1 · balance_after: Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 16:15 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 3 | $2.40 | $7.20 |
DisclosureSEC source: 0001104659-24-104931 · tm2425333-1_4seq1.xml · nonDerivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123 F1 · balance_after: Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 16:54 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001104659-24-102835 · tm2424771-3_4seq1.xml · derivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 16:08 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-23-078094 · tm2320488-3_4seq1.xml · derivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026. F2 · derivative.underlying_shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 16:26 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-152200 · tm2135922-1_4seq1.xml · nonDerivative · entry 2 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,683 F2 · shares: This restricted stock award (RSA) vests on March 15, 2022. F3 · balance_after: Includes 85,668 shares of restricted stock. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 16:26 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 49,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-152200 · tm2135922-1_4seq1.xml · nonDerivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,683 F1 · shares: This restricted stock award (RSA) vests on December 17, 2024, three years after the date granted. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 17:09 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-073825 · tm2022744d2_form4.xml · nonDerivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,663 F1 · shares: Common Stock vests upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen. F2 · balance_after: Includes 84,663 shares of restricted stock. Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 16:17 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-042094 · tv528434_form4.xml · nonDerivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,663 F1 · shares: Common Stock vests upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:43 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 14,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042956 · tv500467_form4.xml · nonDerivative · entry 1 KRANZLER JAY D · CIK 0001055666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,663 F1 · shares: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.